Age is considered to be one of the most important prognostic factor for Glioblastoma (GBM) patients. Elderly patients, age more than 65 years make up a large percentage who are newly diagnosed with GBM. Elderly patients face considerable challenges in tolerating standard therapy and sometime experience significantly shorter survival and poor quality of life compared with non-elderly patients.
Retrospective analysis was done of 72 GBM patients treated with concurrent Temozolamide (TMZ) with 60 Gray of Radiotherapy in 30 fractions followed by 6 cycles of adjuvant TMZ, treated at Square Hospitals Ltd from 2014 to 2017. Overall survival, progression free survival and quality of life were estimated and compared between elderly and non-elderly group.
A total of 72 patients were analyzed, 37 in elderly group and 35 in non-elderly group. The median age was 70 years. Median pre-radiation Karnofsky performance scale (KPS) was 60 (range: 40 - 90). The median overall survival (OS) was 6.8 months and median progression-free survival (PFS) was 4.2 months in elderly patients. However, in non-elderly patients OS was 14 months and PFS was 6 months. Quality of life was poor in elderly GBM patients.
Overall survival and progression free survival were shorter for elderly patients with GBM than for non-elderly patients. Elderly GBM patients need to be considered for less intensive therapy like hypofractionated radiotherapy with or without TMZ. Further prospective randomized studies are needed to find out the appropriate treatment strategy for elderly patient with GBM.
Clinical trial identification
Legal entity responsible for the study
Square Hospitals Ltd.
Has not received any funding.
The author has declared no conflicts of interest.